Incretin Mimetic Drugs
HAVE YOU DEVELOPED PANCREATITIS AFTER TAKING AN INCRETIN MIMETIC DRUG?
Incretin mimetic drugs are used in the treat of type 2 diabetes, oftentimes in combination with other diabetes medications. Incretin mimetic drugs act like incretin hormones, stimulating the release of insulin. These medications can also help suppress appetite by slowing the absorption of glucose into the bloodstream.
There are many different incretin mimetic drugs available to diabetes patients, including:
- Exenatide (Byetta, Bydureon)
- Liraglutide (Victoza)
- Alogliptin (Nesina, Kazano, Oseni)
- Linagliptin (Tradjenta, Jentadueto)
One thing that incretin mimetic drugs have in common is side effects. Most of these adverse effects center on the gastrointestinal tract and may include:
- Loss of appetite
Unfortunately these diabetes medications have drawn heavy attention since their introduction over a decade ago. Many significant health risks, including pancreas issues, have been linked to the use of incretin mimetic drugs for diabetes treatment.
FDA INVESTIGATING RISK OF PANCREATIC CANCER FROM INCRETIN MIMETIC DRUGS
In 2013, the FDA announced that they are investigating a possible increased risk of pancreatitis and pre-cancerous findings of the pancreas from the use of incretin mimetic drugs. Unpublished research findings suggest a link between the diabetes medications and pancreatic duct metaplasia. The findings were based on an examination of pancreatic tissue taken from patients after their death.
Although the FDA has not drawn any conclusions regarding the potential link as of yet, the investigation signals the potential of another risk associated with incretin mimetic drugs.
INCRETIN MIMETIC DRUGS LINKED TO SEVERE PANCREATITIS
The first incretin mimetic drugs hit the shelves in 2005 with the introduction of Byetta. Shortly thereafter, the FDA received many reports of patients developing acute pancreatitis. The agency issued a warning regarding the drugs link, but months later, the FDA had to issue another warning — Byetta could cause severe pancreas inflammation, including necrotizing and hemorrhagic pancreatitis. This warning came just three years after the introduction of incretin mimetic drugs, and now every incretin mimetic drug has the warning on its label.
CONTACT AN EXPERIENCED PHARMACEUTICAL LITIGATION LAWYER
Incretin mimetic drugs have been found to increase the risk of potentially fatal pancreatitis and is currently being investigated as a cause of pancreatic cancer. If you or a loved one has been harmed after taking an incretin mimetic drug such as Byetta and Victoza, contact our experienced dangerous drug attorneys. Thomas J. Henry has the legal resources and experience that you need to take on the pharmaceutical companies. We are available 24/7, nights and weekends to evaluate your claim and provide a free consultation.